CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
F-18 (fallypride)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00801827
NCT00801827Phase 1Completed
CompareCT.gov

PET Imaging and Bariatric Surgery

Vanderbilt University Medical Center·interventional·Posted Dec 4, 2008·Updated Mar 17, 2017

In Brief

A Phase 1 clinical trial evaluating F-18 (fallypride) for Obesity, Morbid. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Morbid
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2008
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.6 years ago

Interventions

F-18 (fallypride)drug

Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.